PCSK9 and ovarian carcinoma: According to the available evidence, lipid-lowering medicines, such as statins, PARP inhibition, fenofibrate, and PCSK9, have been implied to have anti-tumor effects in several human malignancies, including ovarian cancer (68, 75, 76).